Alphavirus Replicon Particles Expressing TRP2 for Melanoma Immunotherapy

Solution Overview

Problem

Current methods for treating melanoma are inadequate, with limited success in vaccine regimens and immunogenic compositions for this aggressive and deadly cancer, particularly lacking an approved vaccine for prevention or therapy.

Innovation Solution

Development of alphavirus replicon particles, specifically Venezuelan Equine Encephalitis Virus (VEE) particles expressing the melanoma antigen dopachrome tautomerase (DCT) or TRP2, to enhance or induce an immune response, administered via various routes to reduce melanoma incidence, severity, and progression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional vaccine regimens are used for melanoma treatment, then the treatment approach is simple and easy to administer, but the success rate and immune response are limited

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses alphavirus replicon particles as an intermediary delivery system to introduce TRP2 antigen into host cells. The viral vector acts as a mediator that efficiently transports the antigen-encoding RNA into target cells, triggering a robust immune response without requiring complex adjuvant combinations or multiple administration routes.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the fundamental parameter of antigen delivery by using replicon particles that can self-replicate within host cells, producing sustained antigen expression. This self-amplifying mechanism transforms a single-dose administration into a prolonged antigen presentation, significantly enhancing immune activation compared to conventional static vaccine formulations.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If alphavirus replicon particles expressing TRP2 are used, then immune response and tumor regression are significantly enhanced, but the manufacturing and production complexity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent segments the viral system into two functional components: replicon particles that carry the TRP2 antigen-encoding RNA and provide self-replication capability, and the antigen gene itself. This segmentation allows the replicon backbone to be pre-characterized and standardized, while only the antigen sequence needs to be customized, simplifying the manufacturing of different vaccine variants.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The replicon particles utilize the host cell's machinery to copy and amplify the TRP2 antigen RNA, creating multiple copies of the antigen within each infected cell. This self-copying mechanism eliminates the need for large-scale production and purification of the antigen protein, significantly reducing manufacturing complexity while maintaining high antigen availability for immune recognition.

Inventive Principle:
Principle #26Copying

3Reliability

If conventional immunogenic compositions are used, then the treatment protocol is straightforward, but the ability to induce strong cellular immune response is insufficient

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical delivery systems (such as adjuvant emulsions, liposomes, or needle injections requiring specific techniques) with a biological delivery system—the alphavirus replicon particle. The viral envelope and capsid structures naturally facilitate cellular entry through endocytosis and membrane fusion, providing efficient antigen delivery without requiring complex formulation chemistry or specialized administration procedures.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach significantly enhances immune responses, leading to significant tumor regression, prolonged survival, and delayed tumor occurrence in mouse models, with potential for human application, demonstrating a potent and cost-effective immunotherapy for melanoma.

Implementation Method 1

alphavirus replicon particles expressing TRP2

Methodology Applied
Scientific EffectViral replication:

Implementation Method 2

expressing the melanoma antigen dopachrome tautomerase (DCT, TRP2)

Methodology Applied
Scientific EffectGene expression:

Data Source

PatentEP2416662B1Alphavirus replicon particles expressing TRP2
Publication Date: 2015.03.25
  • EP2416662B1 patent drawingFigure 1A
  • EP2416662B1 patent drawingFigure 1B
  • EP2416662B1 patent drawingFigure 2

AI summary

The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of tumor regression and /or inhibition of metastasis of a melanoma subject, or a decreased risk of the occurrence or recurrence of melanoma and/or decreased severity of melanoma in a subject not suffering from melanoma at the time of administration. The pharmaceutical composition described herein can be used in conjunction with other therapeutic agents, it can be administered on more than one occasion and it can be combined with administrations of other compositions such as protein or other immunogenic compositions, and/or adjuvants, with beneficial effects to the human or animal subject to which it has been administered.